Eyecare Innovations Today: An Ophthalmic Educational Podcast Series

The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer

11 min · 4. kesä 2024
jakson The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer kansikuva

Kuvaus

In this episode, Anton Hommer, MD, discusses the European perspective on adopting preservative-free pharmaceuticals, highlighting challenges like health care professionals’ reluctancy to change, diverse reimbursement systems, and higher costs. He compares single-use and multiuse drugs, considering factors such as environmental impact and cost-effectiveness. Dr. Hommer emphasizes the superior efficacy of preservative-free medications, especially in treating chronic conditions such as glaucoma, and anticipates an increase in their use to protect ocular health and enhance chronic disease management. This activity is supported by an independent medical education grant from Théa Pharma.

Kommentit

0

Ole ensimmäinen kommentoija

Rekisteröidy nyt ja liity Eyecare Innovations Today: An Ophthalmic Educational Podcast Series-yhteisöön!

Aloita maksutta

14 vrk ilmainen kokeilu

Kokeilun jälkeen 7,99 € / kuukausi. · Peru milloin tahansa.

  • Podimon podcastit
  • 20 kuunteluaikaa / kuukausi
  • Lataa offline-käyttöön

Kaikki jaksot

65 jaksot

jakson The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer kansikuva

The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer

In this episode, Anton Hommer, MD, discusses the European perspective on adopting preservative-free pharmaceuticals, highlighting challenges like health care professionals’ reluctancy to change, diverse reimbursement systems, and higher costs. He compares single-use and multiuse drugs, considering factors such as environmental impact and cost-effectiveness. Dr. Hommer emphasizes the superior efficacy of preservative-free medications, especially in treating chronic conditions such as glaucoma, and anticipates an increase in their use to protect ocular health and enhance chronic disease management. This activity is supported by an independent medical education grant from Théa Pharma.

4. kesä 202411 min